Walleye Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Walleye Capital’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,000	Closed	-$31K	–	3791
2022 Q3	$31K	Buy	+12,000	New	+$29.9K	﹤0.01%	2671
2021 Q3	–	Sell	-40,718	Closed	-$278	–	1886
2021 Q2	$278	Buy	+40,718	New	+$329K	0.01%	972
2020 Q4	–	Sell	-10,600	Closed	-$57K	–	1156
2020 Q3	$57K	Buy	+10,600	New	+$52.5K	0.01%	752
2019 Q3	–	Sell	-36,656	Closed	-$146K	–	2356
2019 Q2	$146K	Buy	+36,656	New	+$174K	0.02%	1092
2018 Q3	$97K	Buy	+10,000	New	+$101K	0.05%	259

Other funds holding PRTK

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Walleye Capital's PRTK Position: Q4 2022 in Review

Walleye Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2022, closing a stake of 12,000 shares — an estimated $31K sold.

Walleye Capital first reported a position in PRTK in Q3 2018 and held it in 5 quarters. The position peaked at $146K in Q2 2019. 76 funds tracked by Wall St. Rank hold PRTK as of Q4 2022.

Walleye Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
Walleye Capital sold 12,000 Paratek Pharmaceuticals, Inc. shares in Q4 2022, an estimated $31K.
Walleye Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2018 and held it in 5 quarters.
Walleye Capital's Paratek Pharmaceuticals, Inc. position peaked at $146K in Q2 2019.
76 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.